AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 9 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1652 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
After suffering development setbacks with regard to two of its late-stage drug candidates, AstraZeneca has signed separate deals with two Asian pharmaceutical companies to help bolster its sparse pipeline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018